Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
1999-08-09
2008-09-02
Canella, Karen (Department: 1643)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C424S093710, C424S277100, C435S326000
Reexamination Certificate
active
07419660
ABSTRACT:
The present invention provides multivalent vaccines for the treatment of B-cell malignancies (e.g., lymphomas and leukemias). The present invention also provides methods for the production of custom vaccines, including multivalent vaccines for the treatment of immune cell tumors malignancies as well as methods of treating immune cell tumors using custom vaccines.
REFERENCES:
patent: 4399216 (1983-08-01), Axel et al.
patent: 4634665 (1987-01-01), Axel et al.
patent: 4656134 (1987-04-01), Ringold
patent: 4683195 (1987-07-01), Mullis et al.
patent: 4683202 (1987-07-01), Mullis
patent: 4956288 (1990-09-01), Barsoum
patent: 4965188 (1990-10-01), Mullis et al.
patent: 5043270 (1991-08-01), Abrams et al.
patent: 5122464 (1992-06-01), Wilson et al.
patent: 5179017 (1993-01-01), Axel et al.
patent: 0 433 900 (1991-06-01), None
patent: 91/13632 (1991-09-01), None
patent: 94/08601 (1994-04-01), None
Stevenson et al (1995) Annals. New York Acad Science vol. 772: pp. 212-226.
Tao et al Nature (1993) vol. 362 pp. 755-758.
Fundamentals of Immunology Ed Bell Paul. Chapter 38 p. 1060-1061; 1066-1067.
Evans et al (QJM Jun. 1999;92(6):299-307).
De The G (Blood Cells 1993;19(3):667-73;discussion 674-5).
Chen TT et al (J. Immunology 1994; 153:4775-4787).
Paul WE Fundamental Immunology 3rd ed, Raven Press 1993, p. 9.
www.hyperdictionary.com —html printout; definition of “idiotype” and “idiotope”.
Cleary et al (Cell, 1986, vol. 44, pp. 97-106).
Levy et al (Journal of Experimental Medicine, 1988, vol. 168, pp. 475-489).
Embleton et al (Nucleic Acids Research, 1992, vol. 20, pp. 3831-3837).
Timmerman et al, Blood, Nov. 16, 2005.
Leonard et al, Blood, Nov. 16, 2003, vol. 102 p. 105A.
Leonard et al, Blood, Nov. 16, 2002, vol. 100, abstract No. 4792).
Briones et al, Blood, Nov. 16, 2001, vol. 98, p. 608A.
Roitt et al, Immunology (text), 1998, pp. 142-143.
Mason, et al.,Myelin Basic Protein Peptides Complexes with the Class II MHC Molecules I-Auamd I-AkForm and Dissociate Rapidly at Neutral pH. Journal of Immunology 154: 5216-5227 (May 15, 1995).
Sambrook, et al.,Molecular Cloning, 16.8-16.15 (1989).
Mason-Kiemle.Interactions of Antigenic Peptides with Class II Major Histocompatibility Molecules, A dissertation submitted to the Program in Biophysics and the Committee on Graduate Studies of Stanford University, Submitted Jan. 1995, Deposited in Falconer Library Sep. 1995.
Walls et al., (1989) “Amplification of Muticistronic Plasmids in the Humaan 293 Cell Line and Secretion of Correctly Processed Recombinant Human—Protein C,”Gene81:139-149.
Maniatis et al., (1987) “Regulation of Inducible and Tissue-specific Gene Expression,”Science236:1237-1244.
Voss et al., (1986) “The Role of Enhancers in the Regulation of Cell Type-Specific Transcriptional Control,”Trends Biochem. Sci. 11:287-289.
Dijkema et al., (1985) “Cloning and expression of the Chromosomal Immune Interferon Gene of the Rat,”EMBO J.4:761-767.
Uetsuki et al., (1989) “Isolation and Characterization of the Human Chromosomal Gene for Polypeptide Chain Elongation Factor-lα,”J. Biol. Chem.264:5791-5798.
Kim et al., (1990) “Use of the Human Elongation Factor 1α Promoter as a Versatile and Efficient Expression System,”Gene91:217-223.
Mizushima and Nagata, (1990) “pEF-BOS, A Powerful Mammalian Expression Vector,”Nuc. Acids. Res., 18:5322.
Gorman et al., (1982) “The Rous Sarcoma Virus Long Terminal Repeat is a Strong Promoter When Introduced into a Variety of Eukaryotic Cells by DNA-mediated Transfection,”Proc. Natl. Acad. Sci. USA79:6777-6781.
Boshart et al., (1985) “A Very Strong Enhancer is Located Upstream of an Immediate Early Gene of Human Cytomegalovirus,”Cell41:521-530.
Sambrook et al., (1989)Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory Press, New York pp. 16.6-16.8, 7.26-7.29, 9.16-9.23.
Schmike et al., (1978) “Gene Amplification and Drug Resistance in Cultured Murine Cells,”Science202:1051-1055.
Kaufman, (1990) “Selection and Coamplification of Heterologous Genes in Mammalian Cells,”Methods in Enzymol., 185:537-565.
Bird et al., (1988) “Single-Chain Antigen-Binding Proteins,”Science242:423-426.
Huston et al., (1988) “Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced inEscherichia coli,” Proc. Natl. Acad. Sci. USA85:5879-5883.
Bebbington et al., (1992) “High-Level Expression Of A Recombinant Antibody From Myeloma Cells Using A Glutamine Synthetase Gene As An Amplifiable Selectable Marker,”Bio/Technology10:169-175.
Dorai and Moore, (1987) “The Effect of Dihydrofolate Reductase-Mediated Gene Amplification on the Expression of Transfected Immunoglobulin Genes,”J. Immunol. 139:4232-4241.
Ausubel et al., (1995)Current Protocols in Molecular Biology, John Wiley & Sons, Inc., at 9.31 to 9.36.
Takebe et al., (1988) “SRα Promoter: An Efficient and Versatile Mammalian cDNA Expression System Composed of the Simian Virus 40 Early Promoter and the R-U5 Segment of Human T-Cell Leukemia Virus Type 1 Long Terminal Repeat,”Mol. Cell. Biol., 8:466-472.
Graham, F.L. et al., (1977) “Characteristics of a Human Cell Line Transformed by DNA From Human Adenovirus Type 5,”J. Gen. Virol., 36:59-72.
Harrison, T., et al., (1977) “Host-Range Mutants of Adenovirus Type 5 Defective for Growth in HeLa Cells,”Virology77:319-329.
Graham, F.L. et al.,(1978) “Defective Transforming Capacity of Adenovirus Type 5 Host-Range Mutants,”Virology86:10-21.
Laimins et al., (1984) “Host Specific Activation of Transcription by Tandem Repeats form Simian Virus 40 and Moloney Murine Sarcoma Virus 40 and Moloney Murine Sarcoma Virus,”Proc. Natl. Acad. Sci. USA79:6453-6457.
Bimboim and Doly, (1979) “A Rapid Alkaline Extraction Procedure for Screening Recombinant plasmid DNA,”Nuc. Acids. Res., 7:1513-1523.
Kaufman and Sharp, (1982) “Amplification and Expression of Sequences Cotransfected with a Modular Dihydrofolate Reductase Complementary DNA Gene,”J. Mol. Biol. 159:601-621.
Kaufman et al., (1985) “Coamplification and Coexpression of Human Tissue-Type Plasminogen Activator and Murine Dihydrofolate Reductase Sequences in Chinese Hamster Ovary Cells,”Mol. Cell. Biol. 5:1750-1759.
Toneguzzo et al., (1988) “Electric Field-Mediated Gene Transfer: Characterization of DNA Transfer and Patterns of Integration In Lymphoid Cells,”Nucl. Acid Res. 16:5515-5532.
Calos et al., (1983) “High Mutation Frequency in DNA Transfected Into Mammalian Cells,”Proc. Natl. Acad. Sci. USA80:3015-3019.
Kopchick and Stacey, (1984) “Differences In Intracellular DNA Ligation After Microinjection and Transfection,”Mol. Cell. Biol. 4:240-246.
Wake et al. (1984) “How Damaged is sThe Biologically Active subpopulation of Transfected DNA?,”Mol. Cell. Biol. 4:387-398.
Lebkowski et al., (1984) “Transfected DNA Is Mutated in Monkey, Mouse, and Human Cells,”Mol. Cell. Biol. 4:1951-1960.
Drinkwater and Klinedinst, (1986) “Chemically Induced Mutagenesis In A Shuttle Vector With A Low-Background Mutant Frequency,”Proc. Natl. Acad. Sci. USA83:3402-3406.
Rice and Baltimore, (1982) “Regulated Expression of An Immunoglobulin K Gene Introduced into a Mouse Lymphoid Cell Line,”Proc. Natl. Acad. Sci. USA79:7862-7865.
Oi et al., (1983) “Immunoglobulin Gene Expression in Transformed Lymphoid Cells,”Proc. Natl. Acad. Sci. USA80:825-829.
Potter et al., (1984) “Enhancer-Dependent Expression of HumanKImmunoglobulin Genes Introduced Into Mouse pre-B Lymphocytes by Electroportation”Proc. Natl. Acad. Sci. USA81: 7161-7165.
Boggs et al., (1986) “Efficient Transformation and Frequent Single-Site, Single-Copy Insertion of DNA Can Be Obtai
Canella Karen
Casimir Jones S.C.
Genitope Corporation
LandOfFree
Vaccines for treatment of lymphoma and leukemia does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Vaccines for treatment of lymphoma and leukemia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vaccines for treatment of lymphoma and leukemia will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3986787